9 research outputs found
Modulation of mitochondrial respiratory function and ROS production by novel benzopyran analogues
A substantial body of evidence indicates that pharmacological activation of mitochondrial ATP-sensitive potassium
channels (mKATP) in the heart is protective in conditions associated with ischemia/reperfusion injury. Several mechanisms have
been postulated to be responsible for cardioprotection, including the modulation of mitochondrial respiratory function. The
aim of the present study was to characterize the dose-dependent effects of novel synthetic benzopyran analogues, derived from
a BMS-191095, a selective mKATP opener, on mitochondrial respiration and reactive oxygen species (ROS) production in isolated
rat heart mitochondria. Mitochondrial respiratory function was assessed by high-resolution respirometry, and H2O2 production
was measured by the Amplex Red fluorescence assay. Four compounds, namely KL-1487, KL-1492, KL-1495, and KL-1507, applied
in increasing concentrations (50, 75, 100, and 150 �mol/L, respectively) were investigated. When added in the last two
concentrations, all compounds significantly increased State 2 and 4 respiratory rates, an effect that was not abolished by
5-hydroxydecanoate (5-HD, 100 �mol/L), the classic mKATP inhibitor. The highest concentration also elicited an important
decrease of the oxidative phosphorylation in a K+ independent manner. Both concentrations of 100 and 150 �mol/L for
KL-1487, KL-1492, and KL-1495, and the concentration of 150 �mol/L for KL-1507, respectively, mitigated the mitochondrial
H2O2 release. In isolated rat heart mitochondria, the novel benzopyran analogues act as protonophoric uncouplers of
oxidative phosphorylation and decrease the generation of reactive oxygen species in a dose-dependent manner
Reversible Inhibition Monoamine Oxidase - A Improves Vascular Dysfunction in Canine Carotid Arteries Exposed to Angiotensin II
Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes
Diabetes mellitus (DM) is widely recognized as the most severe metabolic disease associated with increased cardiovascular morbidity and mortality. The generation of reactive oxygen species (ROS) is a major event causally linked to the development of cardiovascular complications throughout the evolution of DM. Recently, monoamine oxidases (MAOs) at the outer mitochondrial membrane, with 2 isoforms, MAO-A and MAO-B, have emerged as novel sources of constant hydrogen peroxide (H2O2) production in the cardiovascular system via the oxidative deamination of biogenic amines and neurotransmitters. Whether MAOs are mediators of endothelial dysfunction in DM is unknown, and so we studied this in a streptozotocin-induced rat model of diabetes. MAO expression (mRNA and protein) was increased in both arterial samples and hearts isolated from the diabetic animals. Also, H2O2 production (ferrous oxidation - xylenol orange assay) in aortic samples was significantly increased, together with an impairment of endothelium-dependent relaxation (organ-bath studies). MAO inhibitors (clorgyline and selegiline) attenuated ROS production by 50% and partially normalized the endothelium-dependent relaxation in diseased vessels. In conclusion, MAOs, in particular the MAO-B isoform, are induced in aortas and hearts in the streptozotocin-induced diabetic rat model and contribute, via the generation of H2O2, to the endothelial dysfunction associated with experimental diabetes
Mitochondrial Effects of Common Cardiovascular Medications : The Good, the Bad and the Mixed
Mitochondria are central organelles in the homeostasis of the cardiovascular system via the integration of several physiological processes, such as ATP generation via oxidative phosphorylation, synthesis/exchange of metabolites, calcium sequestration, reactive oxygen species (ROS) production/buffering and control of cellular survival/death. Mitochondrial impairment has been widely recognized as a central pathomechanism of almost all cardiovascular diseases, rendering these organelles important therapeutic targets. Mitochondrial dysfunction has been reported to occur in the setting of drug-induced toxicity in several tissues and organs, including the heart. Members of the drug classes currently used in the therapeutics of cardiovascular pathologies have been reported to both support and undermine mitochondrial function. For the latter case, mitochondrial toxicity is the consequence of drug interference (direct or off-target effects) with mitochondrial respiration/energy conversion, DNA replication, ROS production and detoxification, cell death signaling and mitochondrial dynamics. The present narrative review aims to summarize the beneficial and deleterious mitochondrial effects of common cardiovascular medications as described in various experimental models and identify those for which evidence for both types of effects is available in the literature
Modulation of mitochondrial respiratory function and ROS production by novel benzopyran analogues
A substantial body of evidence indicates that pharmacological activation of mitochondrial ATP-sensitive potassium channels (mKATP) in the heart is protective in conditions associated with ischemia/reperfusion injury. Several mechanisms have been postulated to be responsible for cardioprotection, including the modulation of mitochondrial respiratory function. The aim of the present study was to characterize the dose-dependent effects of novel synthetic benzopyran analogues, derived from a BMS-191095, a selective mKATP opener, on mitochondrial respiration and reactive oxygen species (ROS) production in isolated rat heart mitochondria. Mitochondrial respiratory function was assessed by high-resolution respirometry, and H2O2 production was measured by the Amplex Red fluorescence assay. Four compounds, namely KL-1487, KL-1492, KL-1495, and KL-1507, applied in increasing concentrations (50, 75, 100, and 150 mumol/L, respectively) were investigated. When added in the last two concentrations, all compounds significantly increased State 2 and 4 respiratory rates, an effect that was not abolished by 5-hydroxydecanoate (5-HD, 100 mumol/L), the classic mKATP inhibitor. The highest concentration also elicited an important decrease of the oxidative phosphorylation in a K+ independent manner. Both concentrations of 100 and 150 mumol/L for KL-1487, KL-1492, and KL-1495, and the concentration of 150 mumol/L for KL-1507, respectively, mitigated the mitochondrial H2O2 release. In isolated rat heart mitochondria, the novel benzopyran analogues act as protonophoric uncouplers of oxidative phosphorylation and decrease the generation of reactive oxygen species in a dose-dependent manner